ESMO 2024 Focus on GU Oncology Podcast

Welcome to Medicom’s ESMO Focus on Genitourinary Tumours, where we bring the Congress to the Physician by bringing you the latest and most impactful developments in medical research. I’m your host, Dr Rachel Giles, and today we’re continuing our exploration of the latest GU oncology research reported at the European Society of Medical Oncology or -ESMO2024- that’s reshaping treatment approaches across different cancers. In this episode, we’ll cover 6 groundbreaking studies that focus on renal cell carcinoma, prostate cancer, and bladder cancer, highlighting promising therapies and new insights. If you’re a healthcare professional, this episode is full of essential updates to keep you informed.

Segment 1: Tivozanib Monotherapy – A Post-ICI Option in RCC

Segment 2: CONTACT-02 Trial – Advancing Prostate Cancer Therapy

Segment 3: Radium-223 and Enzalutamide in Bone Metastases

Segment 4: Darolutamide and ADT for Metastatic Prostate Cancer in ARANOTE

Segment 5: Fecal Transplants in Metastatic RCC Treatment

Segment 6: Neoadjuvant Durvalumab in Muscle-Invasive Bladder Cancer

Today’s episode covers some of the most impactful studies in GU oncology, from advanced renal cell carcinoma to castration-resistant prostate cancer and muscle-invasive bladder cancer. These trials not only highlight new therapeutic options but also provide crucial insights into the evolving understanding of how we can better tailor treatments to improve patient outcomes. Thank you for joining us for this deep dive into cutting-edge cancer research. I hope these findings will inspire you to re-evaluate treatment strategies in your practice and explore how these innovations could benefit your patients. Until next time, stay curious and keep advancing the field of medicine!

 



Posted on 19 September 202420 September 2024